Medical device manufacturers operate estates that change faster than an annual or semi-annual assessment cycle can describe. Exposure concentrates in the interfaces connecting systems to suppliers, clinicians, and cloud platforms, and conventional testing scopes are often thinnest precisely there. By bringing testing in-house, this manufacturer replaced a twice-yearly report with a capability their own team operates, extended coverage from a negotiated sample to networks, websites, and APIs across the estate, and closed the gap between discovering an exploitable risk and confirming that they fixed it.
